Close Menu
Skip to main content
GenomeWeb
360Dx
Precision Oncology News
Precision Oncology News
*
*
Show password
Forgot your password?
Subscribe
Contains all of these words:
You may find more results for this query on our sister sites:
GenomeWeb
and
360Dx
.
Business & Policy
Business News
Regulatory News
Reimbursement
Biomarkers
BRCA
EGFR
HER2
KRAS
BRAF
ROS1
ALK
PD-L1
Cancer Specialties
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Brain Cancer
Melanoma
Pediatric Cancer
Oncology Trends
Next-Generation Sequencing
Minimal Residual Disease
Microsatellite Instability Testing
Immunotherapy
Liquid Biopsy
Resources
Webinars
White Papers
Conferences & Events
Menu
Home
›
About Us
›
Our Staff
›
Allan Nixon
Allan Nixon
Director of Business Development, Premium Content
Phone Number
+1-212-651-5623
Email
[email protected]
Breaking
News
European Commission Approves Takeda's Alunbrig for First-Line ALK-positive Lung Cancer
Myriad Genetics BRCA Test to be Reimbursed in Japan
NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer
Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women
VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan
BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers
